中国经济网北京2月2日讯 智翔金泰(688443.SH)日前披露2025年年度业绩预告。经财务部门初步测 算，公司预计2025年年度实现营业收入20,944.98万元到25,087.94万元，与上年同期相比增加17,935.48万 元到22,078.44万元，同比增长595.96%到733.62%。 公司预计2025年年度归属于母公司所有者的净利润为-48,063.73万元到-58,744.56万元，与上年同期 相比，亏损减少20,982.80万元到31,663.63万元，同比减少26.32%到39.71%；归属于母公司所有者扣除 非经常性损益后的净利润为-52,363.18万元到-63,044.01万元，与上年同期相比，亏损减少17,388.95万元 到28,069.78万元，同比减少21.62%到34.90%。 2021年至2024年，智翔金泰归属于上市公司股东的净利润分别为-3.22亿元、-5.76亿元、-8.01亿 元、-7.97亿元；归属于上市公司股东的扣非净利润分别为-3.34亿元、-6.45亿元、-8.13亿元、-8.04亿 元。 智翔金泰于2023年6月20日在上交所科创板上市，公开发行新股9 ...

Core Viewpoint - The company Zhixiang Jintai (688443) is experiencing significant financial challenges, with projected losses for 2025 and a focus on product development in the autoimmune disease sector. Financial Performance - As of January 30, 2026, Zhixiang Jintai's stock closed at 28.29 yuan, down 3.25% from the previous week [1] - The company expects a net profit loss of 524 million to 630 million yuan for the year 2025 [1] - Projected operating revenue for 2025 is between 209 million and 251 million yuan [1] - The expected net profit loss attributable to shareholders is between 481 million and 587 million yuan [1] - The total market capitalization is 10.373 billion yuan, ranking 28th out of 51 in the bioproducts sector and 1969th out of 5184 in the A-share market [1] Product Development and Clinical Trials - The GR1802 injection (Tairiqibai monoclonal antibody) for moderate to severe atopic dermatitis has had its new drug application accepted as of September 2025 and is currently under review [2] - Other indications for GR1802, including chronic sinusitis with nasal polyps and chronic spontaneous urticaria, are in Phase III clinical trials, while asthma is in Phase II [2] - The GR1803 injection for multiple myeloma has received conditional approval for listing and is on the priority review list [7] Strategic Partnerships and Market Positioning - The company is strategically focusing on the autoimmune disease sector, particularly with the commercialization of its products [2] - The inclusion of the product Sairiqi monoclonal antibody in the national medical insurance directory is expected to enhance hospital access and reduce patient costs, thereby improving treatment adherence [2] - The company has established a professional business development team to explore potential partnerships and collaborations [3] Revenue Growth and Cost Management - The sales revenue from the product Jinlixi is expected to drive a nearly sixfold increase in revenue for 2025 [5] - Research and development expenses are projected to be between 425 million and 519 million yuan, reflecting a year-on-year decrease of 14.77% to 30.27% [8] - The anticipated net profit loss is expected to decrease by 26.32% to 39.71% compared to the previous year, primarily due to increased sales and the absence of share-based payment expenses in 2025 [8]

本报讯 （记者冯雨瑶）1月29日晚间，重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"）发布2025年度业绩预 告，经财务部门初步测算，预计2025年实现营业收入2.09亿元至2.51亿元，较上年同期增加1.79亿元至2.21亿元，同比大幅增长 595.96%至733.62%；预计2025年年度归属于母公司所有者的净利润为-4.81亿元至-5.87亿元，与上年同期相比，亏损同比减少 26.32%至39.71%。预计归属于母公司所有者扣除非经常性损益后的净利润为-5.24亿元至-6.30亿元，与上年同期相比，亏损同 比减少21.62%至34.90%。 报告期内，公司坚持源头创新，高效推进各在研项目进度。随着多款产品进入临床研究阶段及核心产品进入关键临床试验 阶段，公司对在研项目保持较高水平的研发投入。同时，公司2022年针对核心团队实施的股权激励计划服务期已于2024年届 满，2025年度无股份支付费用，因此报告期内相应费用减少。 在上述因素的综合作用下，公司预计2025年度归属于母公司所有者的净利润及归属于母公司所有者的扣除非经常性损益的 净利润均为亏损，但亏损幅度较上年同期显著收窄。 （编辑 张伟） ...

重庆智翔金泰生物制药股份有限公司2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 证券代码：688443 证券简称：智翔金泰 公告编号：2026-004 3、2024年归属于母公司所有者的净利润为-79,727.36万元。 4、2024年归属于母公司所有者的扣除非经常性损益的净利润为-80,432.96万元。 （二）业绩预告情况 1、经财务部门初步测算，预计2025年年度实现营业收入20,944.98万元到25,087.94万元，与上年同期相 比增加17,935.48万元到22,078.44万元，同比增长595.96%到733.62%。 2、经财务部门初步测算，预计2025年研发费用为42,521.28万元到51,970.45万元，与上年同期相比减少 9,008.74万元到18,457.91万元，同比减少14.77%到30.27%。 3、预计2025年年度归属于母公司所有者的净利润为-48,063.73万元到-58,7 ...

智通财经APP讯，智翔金泰(688443.SH)发布2025年年度业绩预告，预计2025年年度归属于母公司所有 者的净利润为-48,063.73万元到-58,744.56万元，与上年同期相比，亏损减少20,982.80万元到31,663.63万 元，同比减少26.32%到39.71%。 报告期内，公司营业收入较上年同期实现大幅增长，主要原因系公司首款商业化产品赛立奇单抗注射液 (金立希®)销售收入稳步增长，以及确认GR1803注射液授权许可及商业化协议的合同履约义务所对应的 授权许可收入。 报告期内，公司坚持源头创新，高效推进各在研项目进度。随着多款产品进入临床研究阶段及核心产品 进入关键临床试验阶段，公司对在研项目保持较高水平的研发投入。同时，公司2022年针对核心团队实 施的股权激励计划服务期已于2024年届满，2025年度无股份支付费用，因此报告期内的相应费用减少。 ...

智翔金泰(688443.SH)发布2025年年度业绩预告，预计2025年年度归属于母公司所有者的净利润 为-48,063.73万元到-58,744.56万元，与上年同期相比，亏损减少20,982.80万元到31,663.63万元，同比减 少26.32%到39.71%。 报告期内，公司营业收入较上年同期实现大幅增长，主要原因系公司首款商业化产品赛立奇单抗注射液 (金立希)销售收入稳步增长，以及确认GR1803注射液授权许可及商业化协议的合同履约义务所对应的 授权许可收入。 报告期内，公司坚持源头创新，高效推进各在研项目进度。随着多款产品进入临床研究阶段及核心产品 进入关键临床试验阶段，公司对在研项目保持较高水平的研发投入。同时，公司2022年针对核心团队实 施的股权激励计划服务期已于2024年届满，2025年度无股份支付费用，因此报告期内的相应费用减少。 ...

Core Viewpoint - Zhixiang Jintai (688443) forecasts a net profit loss of between 481 million to 587 million yuan for 2025, with a year-on-year reduction in losses by 26.32% to 39.71% [1] Group 1: Financial Performance - The company expects significant revenue growth compared to the previous year, primarily driven by steady sales of its first commercial product, Saliqi monoclonal antibody injection (Jinlixi) [1] - The revenue increase is also attributed to the recognition of licensing income from the GR1803 injection licensing and commercialization agreement [1] Group 2: Research and Development - The company maintains a high level of R&D investment as multiple products enter clinical research phases and core products advance to critical clinical trial stages [1] - There will be no share-based payment expenses in 2025 due to the expiration of the equity incentive plan for the core team implemented in 2022, leading to a reduction in corresponding expenses [1] Group 3: Overall Outlook - Despite the anticipated net loss for 2025, the company expects a significant narrowing of the loss compared to the previous year [1]

Core Viewpoint - The company expects a significant reduction in net losses for the fiscal year 2025, indicating improved financial performance compared to the previous year [1] Financial Performance - The projected net profit attributable to the parent company for 2025 is expected to be between -480.64 million and -587.45 million yuan, representing a decrease in losses by 209.83 million to 316.64 million yuan, or a year-on-year reduction of 26.32% to 39.71% [1] - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between -523.63 million and -630.44 million yuan, with a decrease in losses by 173.89 million to 280.70 million yuan, translating to a year-on-year reduction of 21.62% to 34.90% [1] Research and Development - The company is committed to innovation at the source and is efficiently advancing the progress of various research projects [1] - Several products are entering clinical research phases, and core products are entering critical clinical trial stages, maintaining a high level of R&D investment [1] - The company will not incur share-based payment expenses in 2025, as the equity incentive plan for the core team implemented in 2022 will expire in 2024, leading to a reduction in corresponding expenses during the reporting period [1]

Core Viewpoint - Zhixiang Jintai (688443.SH) expects a net loss attributable to shareholders of 481 million to 587 million yuan for 2025, primarily due to increased sales revenue from its first commercial product, Sailiqi monoclonal antibody injection, and recognition of licensing income from GR1803 injection [1] Financial Performance - The anticipated net loss for 2025 is projected to be between 481 million yuan and 587 million yuan [1] - The performance fluctuation is attributed to the growth in sales revenue from the commercialized product and the confirmation of licensing income [1] Cost Management - The company will not incur share-based payment expenses in 2025 due to the expiration of the stock incentive service period [1] - Research and development expenses are expected to decrease year-on-year [1]

Revenue Projections - The company expects 2025 annual revenue to be between 209.45 million and 250.88 million CNY, an increase of 179.35 million to 220.78 million CNY compared to the previous year, representing a growth of 595.96% to 733.62%[2] - The significant increase in revenue is primarily due to the steady growth in sales of the company's first commercialized product, the Saliqi monoclonal antibody injection, and revenue from the GR1803 injection licensing agreement[6] R&D Expenses - The estimated R&D expenses for 2025 are projected to be between 425.21 million and 519.70 million CNY, a decrease of 90.09 million to 184.58 million CNY from the previous year, reflecting a reduction of 14.77% to 30.27%[2] - The company maintains a high level of R&D investment as multiple products enter clinical research and core products reach critical clinical trial stages[6] Net Loss Projections - The expected net loss attributable to the parent company for 2025 is projected to be between -480.64 million and -587.45 million CNY, a reduction of 209.83 million to 316.64 million CNY compared to the previous year, indicating a decrease of 26.32% to 39.71%[2] - The net loss attributable to the parent company after deducting non-recurring gains and losses is expected to be between -523.63 million and -630.44 million CNY, with a reduction of 173.89 million to 280.70 million CNY compared to the previous year, representing a decrease of 21.62% to 34.90%[3] Expense Management - The company will not incur share-based payment expenses in 2025 due to the expiration of the stock incentive plan for the core team implemented in 2022, contributing to reduced expenses[6] Financial Forecast Integrity - The financial data in this forecast is based on preliminary calculations by the company's finance department and has not yet been audited by a registered accountant[7] - The company has not identified any significant uncertainties that could affect the accuracy of this earnings forecast[7]